Article
Pediatrics
Julie Bernardor, Sacha Flammier, Jean-Pierre Salles, Cyril Amouroux, Mireille Castanet, Anne Lienhardt, Laetitia Martinerie, Ivan Damgov, Agnes Linglart, Justine Bacchetta
Summary: In this study, the French experience in using Cinacalcet for pediatric primary hyperparathyroidism (PHPT) was reported. The results showed that Cinacalcet can effectively control hypercalcemia and parathyroid hormone (PTH) levels without significant side effects.
FRONTIERS IN PEDIATRICS
(2022)
Review
Endocrinology & Metabolism
Manju Chandran, John P. Bilezikian, Joel Lau, Reshma Rajeev, Samantha Peiling Yang, Miny Samuel, Rajeev Parameswaran
Summary: This study conducted a systematic review and meta-analysis to evaluate the safety and efficacy of Cinacalcet in patients with primary hyperparathyroidism (PHPT). The findings suggest that Cinacalcet can effectively lower serum calcium and PTH levels in PHPT patients, with a greater impact on calcium levels in the short term. The drug is safe with tolerable side effects.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS
(2022)
Article
Endocrinology & Metabolism
Nardeen B. Dawood, Chi-Hong Tseng, Dalena T. Nguyen, Kimberly L. Yan, Masha J. Livhits, Angela M. Leung, Michael W. Yeh
Summary: PHPT, a common cause of hypercalcemia and secondary osteoporosis, is often underdiagnosed. A retrospective cohort study revealed that more than half of patients with confirmed hypercalcemia were not assessed for PHPT, leading to missed opportunities to avoid skeletal and other complications. Care gaps in BMD assessment and therapy represent areas for improvement in PHPT management.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
J. G. Timmons, R. Manners, M. Bailey, C. McDougall
Summary: Primary hyperparathyroidism (pHPT) can lead to mild symptoms but have an impact on cognition and function. In elderly patients, watchful waiting may be a clinically appropriate choice. Through medication treatment, significant improvement in functional and cognitive deficits can be achieved.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM
(2021)
Article
Endocrinology & Metabolism
Natalia G. Mokrysheva, Anna K. Eremkina, Alina R. Elfimova, Elena V. Kovaleva, Anastasiia P. Miliutina, Ekaterina E. Bibik, Anna M. Gorbacheva, Ekaterina A. Dobreva, Irina S. Maganeva, Julia A. Krupinova, Rustam H. Salimkhanov, Lizaveta A. Aboishava, Elena V. Karaseva, Galina A. Melnichenko, Ivan I. Dedov
Summary: The aim of this study was to estimate the clinical and biochemical profile, complications, surgical intervention, and medical therapy of patients with primary hyperparathyroidism (PHPT) in the Russian Federation. The results showed that the detection rate of PHPT has increased in recent years, but most patients still had significant alterations in phosphorus-calcium metabolism, indicating delayed diagnosis and the need for further improvement in medical care.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Urology & Nephrology
Aileen X. Wang, Sai Liu, Maria E. Montez-Rath, Glenn M. Chertow, Colin R. Lenihan
Summary: This study aims to examine the incidence, associations, and outcomes of posttransplant parathyroidectomy and calcimimetic use in a cohort of Medicare-insured US kidney transplant recipients. The study found that the rate of posttransplant parathyroidectomy remained stable over time, while the use of calcimimetic increased during the study period. Long dialysis vintage and pre-transplant calcimimetic use were strongly associated with posttransplant parathyroidectomy and calcimimetic use. Roughly 1 in 4 patients were hospitalized within 90 days of posttransplant parathyroidectomy, with hypocalcemia-related diagnoses being the most common complication. Parathyroidectomy was not associated with an increase in acute kidney injury compared to calcimimetic initiation.
AMERICAN JOURNAL OF KIDNEY DISEASES
(2023)
Article
Endocrinology & Metabolism
Latoya A. Stewart, Gabrielle K. Steinl, Bernice L. Huang, Catherine McManus, James A. Lee, Jennifer H. Kuo, Marcella D. Walker
Summary: In a retrospective cross-sectional study comparing cardiac conduction in patients with primary hyperparathyroidism (PHPT) or thyroid disease (TD), it was found that PHPT patients had shorter QTc intervals compared to TD controls. However, there was no significant difference in the prevalence of arrhythmia between the two groups.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Robert A. Wermers, Marcio L. Griebeler, Prabin Thapa, Matthew A. Hathcock, Ann E. Kearns
Summary: Overall, the survival of patients with primary hyperparathyroidism (PHPT) in a community population in the United States was not significantly different from that of white Minnesota residents. However, individuals with a maximum serum calcium level > 10.8 mg/dL had an increased risk of mortality. Survival was improved after parathyroidectomy in patients with serum calcium levels >10.8 mg/dL.
Article
Surgery
Thomas Szabo Yamashita, Hallbera Gudmundsdottir, Trenton R. Foster, Melanie L. Lyden, Benzon M. Dy, Peter J. Tebben, Travis McKenzie
Summary: This study retrospectively reviewed the data of pediatric patients (<= 21 years) undergoing surgery for primary hyperparathyroidism (PHPT). The results showed that PHPT is rare in children and mostly sporadic. Familial cases have higher recurrence rates and require closer follow-up.
AMERICAN JOURNAL OF SURGERY
(2023)
Article
Surgery
Matthew Behrens, Shawna Boyle, Abbey L. Fingeret
Summary: The study showed that many patients with nephrolithiasis are not assessed for hypercalcemia or hyperparathyroidism, indicating potential significant delays in receiving parathyroidectomy. Targeted interventions such as electronic health record alerts or automated reflex testing may improve care in this area.
JOURNAL OF SURGICAL RESEARCH
(2021)
Review
Medicine, General & Internal
Dalal S. Ali, Karel Dandurand, Aliya A. Khan
Summary: During pregnancy, diagnosis and management of primary hyperparathyroidism require close monitoring of serum calcium levels. Medical management options are limited and surgery is advised during the 2nd trimester in the presence of severe hypercalcemia. Hypercalcemia should be avoided to minimize maternal and fetal complications.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
Natasha M. Appelman-Dijkstra, Stefan Pilz
Summary: Taking care of pregnant patients with parathyroid disorders requires consideration of changes in bone and mineral metabolism. The diagnostic and therapeutic approaches differ from the nonpregnant population. Parathyroidectomy is recommended for primary hyperparathyroidism before pregnancy to reduce complications. Conservative treatment and active surveillance are recommended for hypoparathyroidism. Postpartum monitoring is necessary, as there is an increased risk of hypercalcemia.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Paul M. Bunch, Christopher J. Nguyen, Erik D. Johansson, Reese W. Randle
Summary: This study aimed to assess the importance of routine CT in the diagnosis of primary hyperparathyroidism. The results showed that enlarged parathyroid glands were frequently visible on CT images, which corresponded to pathologically proven parathyroid lesions. Almost half of the patients developed hyperparathyroidism-related comorbidities between CT and subsequent biochemical screening.
ACADEMIC RADIOLOGY
(2023)
Article
Surgery
Matrix Man-Him Fung, Dick-Sang Tam, David Tak-Wai Lui, Brian Hung-Hin Lang
Summary: In severe renal hyperparathyroidism (RHPT), it is uncertain whether administering Cinacalcet before total parathyroidectomy can reduce post-operative hypocalcemia. We compared post-operative calcium kinetics between patients who took Cinacalcet before surgery (Group I) and those who did not (Group II).
WORLD JOURNAL OF SURGERY
(2023)
Article
Medicine, General & Internal
Nadir Alpay, Alaattin Yildiz
Summary: This retrospective study investigated the effect of cinacalcet therapy on kidney and patient survival in patients with secondary hyperparathyroidism after renal transplantation. The results showed that cinacalcet treatment effectively reduced patients' calcium levels, but had no significant effect on parathyroid hormone levels. Cinacalcet therapy is a feasible option for patients with secondary hyperparathyroidism after renal transplantation.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2023)